Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.986 EUR | +1.96% | +0.85% | +28.51% |
May. 07 | AstraZeneca target raised; Antofagasta lowered | AN |
May. 03 | AIB buys back EUR999 million worth of shares from Irish government | AN |
Summary
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Its low valuation, with P/E ratio at 7.01 and 7.29 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company appears to be poorly valued given its net asset value.
- The company is one of the best yield companies with high dividend expectations.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Sales forecast by analysts have been recently revised upwards.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analyst opinion has improved significantly over the past four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Banks
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+28.51% | 13B | B+ | ||
+16.85% | 571B | C+ | ||
+14.20% | 301B | C+ | ||
+18.59% | 252B | C+ | ||
+25.74% | 216B | C | ||
+21.29% | 183B | B- | ||
+25.50% | 170B | B- | ||
+9.52% | 162B | C+ | ||
+5.28% | 146B | B- | ||
-15.88% | 131B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- A5G Stock
- Ratings AIB Group plc